Knowing the epitope specificities of our monoclonal antibodies (MCA) to human choriogonadotropin (hCG), we could design three classes of two-site immunoradiometric assays (IRMA): a combinationof two MCA recognizingtwo separate a-epitopes (a-MCA) provides a system (i.e., an a-IRMA) that measures holo-hCG plus free a-subunitsplus follitropin, lutropin, and thyrotropin, whereas a /3-IRMA, consistingof two /3-MCA, quantifies holo-hCG plus free /3-subunits. The amount of either of the two subunitscan be calculated by subtractingthe amountof holo-hCGdeterminedin parallelin a holo-hCG-IRMA. In the latter,one of the a-or f3-MCA may be eithercross-combinedor,preferably, pairedwith an MCA specific for a conformational epitope.These analyticalspeci- and ectopicaily by various nontrophoblastic tumors (ovary, uterus, pancreas), and perhaps even by normal somatic cells (for a review see ref.
much as 100% with lutropin, but more recent protocols in which the antigen used is either the /3-subunit of hCG (3) or its carboxy-terminal peptide extension (by which it differs from lutropin) yielded more specific immune responses (4). Still, the affinity-i.e., the assay sensitivity-of such antisera occasionally seems to be inversely related to the molecular size of the immunogen (4) . Despite such technical improvements, "discordant" (5), "aberrant" (6) , or even "inconsistent qualitative" (7-9) results of hCG measurements have been observed. Consequently, parallel application of different kits based on different methodological principles has been advocated (9, 10), because such differently based immunoassays are subject to interference in different ways. These include the structural similarity of hCG to lutropin (11), the heterogeneity in the carbohydrate content of hCG (12, 13), the presence of free subunits (14) and other fragments (15, 16), the possible coexistence of hCG with antibodies against hCG (17) or against rabbit immunoglobulin (18), variations in the content of serine proteases in plasma (19) , and other variations in the sample matrix (reviewed in 2, 10,20).
Sophisticated maneuvers such as multiple absorptions or chromatographic sample-purification steps are often required, to render polyclonal antisera completely specific. Moreover, antisera to isolated subunits of hCG are of very limited availability. Thus, monoclonal antibodies (MCA) appear to be advantageous in several aspects: not only can they be obtained in unlimited quantities, facilitating assay standardization, but also, as shown in this paper, they can be selected more rationally and combined with one another so as to establish immunoassays that may have greater specificity than their constituent reagents alone. As reported (21) , even their affinities can be enhanced by such a socalled cooperative immunoassay.
We have produced several different purified IgG-MCA to hCG of defined primary specificities-i.e., a-, /3-, or c-(= conformational)
(22)-and
affinities (23) . We have assessed their exact epitope specificities. In consequence, we were able to construct an epitope map of hCG (1). On this basis, we report here the application of five of 21 MCA against hCG as selected reagents used in three different two-site immunoradiometric assays (nua) that allow concurrent measurement of both intact hCG ("holo-hCG") and its free a and /3subunits in various standard preparations and clinical samples.
MaterIals and Methods

Two-Site IRMA
As previously described in detail (1), the technique adopted for the following studies was a two-site nm in which hCG was complexed between two MCA that recognize two different and sterically distant epitopes. One of these MCA, which we called the "capture-MCA," is coated onto 12 x 75 mm polystyrene tubes. The other, the "detection-MCA," is iodinated with Namil by the Chloramine T method (24 yield of specific radioactivity is on the order of 1500 to 1800 Ci per millimole of IgG. Ten micrograms of IgG-MCA in 0.3 mL of bicarbonate buffer (10 mmoL'L, pH 9.6) is allowed to adsorb to the inner wall of the tubes, resulting in approximately 10 nmol of IgG remaining stably bound. We assessed this by a saturation experiment (1), using iodinated hCG, and by Scatchard plot evaluation with use of a previously published computer program (25) . Tubes prepared in this way were incubated for 60 mm at 37#{176}C with various concentrations of standard hCG (0.2-2000 mt. units/L) in 0.2 mL of assay buffer (phosphate buffer, 50 inmol/L, pH 7.4, supplemented with 3.3 g of bovine serum albumin per liter), followed by two rinses with phosphate-buffered isotonic saline. We then added 200 000 cpm (corresponding to about 0.5 nmol of IgG) of the detection-MCA. We terminated the reaction after a further 90 mm at 37#{176}C by rinsing the tube three times with phosphate-buffered isotonic saline. The radioactivity bound to the tube was then counted.
Design of Three Types of hCG-IRMAS
The basis for the design of MA5 for the selective and differential quantification of holo-hCG and its free subunits was our epitope map of hCG (1). It displays nine different epitopes. Figure 1 shows a simplified version. From this map, the predicted specificities of three types of ms, referred to as a-m, (3-nt, and holo-hCG-m, could be delineated, as schematically depicted in Figure 2 . Accordingly, the combination of an a2-capture-MCA with a radiolabeled a3-detection-MCA recognizes hCG via its a-subunit. This a-nu should measure free a-subunits but also holehCG and, if present, all the other glycoprotein hormones (foflitropin, lutropin, and thyrotropin) as well, because they all possess the same a-chain as hCG.
By analogy, a /3-ma, consisting of two /3-MCA, such as f31-capthre MCA and a j33-detection-MCA, complexes the (3-facet of hCG, thus quantifying free (3-subunits and holo-hCG without interference by other glycoprotein hormones. Not even lutropin would interfere, because the /31-epitope has been shown to be expressed neither by human lutropin nor species. This contrasts with all other /3-epitopes (i.e., /32, /33, and /34), which apparently represent evolutionarily highly conserved structures.
Holo-hCG alone should, in principle, be selectively quantified by simply cross-combining the aforementioned f3-capture-MCA with the a3-detection-reagent. The other cross-combination-i.e., a2-capture-MCA with the /33-detection-MCA-would also react with lutropin. Quite obviously, the structural integrity of the hCG molecule is the prerequisite for such holo-hCG-mtas being operative. Thus, with only four different MCA, three different molecular species of hCG can be measured selectively by three different mrs.
Use of an additional reagent, such as a c-MCA, as the capture-MCA enables preselection of holo-hCG without interference from free subunits, because these are removed by washing before the detection step in a kind of affinity purification.
Holo-hCG, complexed to such a solidphase c-MCA, can then be developed by adding the a3-or the /33-detection-MCA, the same as those being used in the respective a-or (3-mr&As, or by adding both of them for possible signal enhancement.
In particular, for use in the ms described below, we selected MCA having the following code numbers: We also set up an inverse holo-hCG-mz to study the effects of excess amounts of free (3- 
Results
Assay Stability, Precision, Sensitivity
One of these mr.s, namely the inverse holo-hCG-nm (no. 4 above), was subjected to a long-term stability testing. Even though, as shown in Figure 3 , the signal yield steadily declined with the time elapsed between preparation and actual use of the reagents (this decline being most prominent with the precoated tubes), the precision of the measurement of the control samples was equal in both systems (i.e., precoated and freshly coated tubes): the between-batch CVs were 12%, 8%, and 6%, respectively, for control samples containing 54, 180, and 650 mt.units of hCG per liter. In all other experiments described below we used only freshly prepared tubes and tracers that were not older than six weeks.
The minimum detectable amount, defined by the concentration interpolated from the curve at the signal level three standard deviations above the zero signal, was between 0.2 and 1 mt. unitfL for all these ms, the actual value depending on the shelf life of the reagents used. For practical reasons, we designate here 1 mt. unit/L as the cutoff value, even when the calculated sensitivity was better.
Assay Accuracy and Specificity
As shown in Table 1 , we could account for 100% of the 1st hCG ("for bioassay") as well as Pregnyl#{174} (a therapeutic hCG preparation) in terms of activity (int. units). In contrast, in the f3-mrA, the apparent concentration readings were fourto sixfold higher, indicating contamination of these preparations with bio-inactive free /3-subunits.
Added free a-and /3-subunits (standard preparations from the U.S. National Institutes of Health) could only be detected in the corresponding a-or /3-ntr.s. Neither was detectable in the holo-hCG-uu,tA or in the non-corresponding subunit-iius.
Apparently, these NIH subunit preparations are not contaminated with any detectable amount of holohCG or opposite subunit.
Addition of free subunits to the 1st IRP of hCG, which contains only holo-hCG, led to additive concentration readings only in the corresponding subunit-iiust.&s, but did not affect results for the holo-hCG-nustt.
Pituitary glycoprotein hormone standards for follitropin, lutropin, and thyrotropin were detected in the a-but not in the holo-hCG-mMA, as expected. .,INN-hCG-1 5) as I-labeled detecfion-MCA (an asterisk always denoting a detection-MCA In this paper). Accordingly, 'p-p" is the constellation for a p-IRMI. c-/3" for the holo-hCG-unw and "/3-c" for the "Inverse" holo-hCG-ii'iw. In completeparallel fashion, ineach ofthe tmss graded amounts of pure holo-hCG(i.e., 1st IRP), of holo-hCG contaminated with free /3-subunits (i.e.,2nd IS in the different IRMA systems. Depending on the particular assay configuration, free subunits as standards either produce standard curves that parallel that for the 1st IRP for holo-hCG or they are not detectable at all. By contrast, solutions containing holo-hCG plus free (3-subunits, such as the 2nd IS or Pregnyl, either give completely superimposable (such as in the cilssI/3a holo-hCG-IRMA) or segregated dilution curves (such as in the inverse holo-hCG-inr, i.e., /32-'I-c1), sometimes including a so-called high-dose hook effect. This comparative analysis stresses the importance of using a reference preparation of defined molecular composition as calibrator in any kind of hCG immunoassay.
Apparently, the only material that is free of isolated subunits is the 1st IRP. Any tertiary standard (i.e., any standard used in a kit or prepared inhouse to replace use of this reference substance in routine hCG determinations)
should be composed as similarly as possible to the 1st 1RP.
Clinical Applications
After proving the analytical validity of these mMAs, we assayed some clinical and biological samples. Apparently, only holo-hCG is present in sera from normal late pregnancies (as assessed by normal estriol concentrations), because the results did not differ among the different mi.s. However, a sample of serum from a patient with hydatidiform mole also contained free /3-subunit, reflecting unbalanced hCG secretion.
For urine samples from normal pregnant women experiencing a normal first trimester, the abundance of free (3-subunits is quite obvious, thus well explaining the contamination of preparations derived from early-pregnancy urine, such as 2nd IS or Pregnyl, with free /3-subunits as suggested above. However, free a-subunits were not demonstrable in early-pregnancy urine with these m#{174}s. Free /3-subunits were not detected in serum, which would indicate that circulating holo-hCG is rapidly metabolized-i.e., dissociated into the subunits, which are promptly cleared from the serum to urine-and that the resulting /3-subunits apparently preserve their immunological integrity throughout pregnancy whereas the free a-subunits do so only in late pregnancy.
In undiluted sera from patients with verified seminoma (who had a-fetoprotein concentrations ranging from undetectable to much above normal) only little hCG-like immunoreactivity was found, and the apparent concentrations were about the same in all three IRMAB. By contrast, for sera from patients with verified trophoblastic tumor we could distinguish four types of secretory patterns, as exemplified in Table 2 :
(a) patients with concordant readings in all three utMAs; (b) patients with higher readings for the a-m as compared with the holo-hCG-n; (c) patients with higher readings for the (3-IRMA as compared with the holo-hCG-ntMA; and (d) patients in whom both subunits-niMAs gave concentration readings exceeding those for the holo-hCG-IRMA to various extents. Table 2 shows that similar constellations were found in supernates from a culture of a choriocarcinoma cell line, "JAr". In supernates taken after 2 h of culture, none of the utMA detected any immunoreactive material.
By 6 h free asubunits were detectable, and by 96 h holo-hCG and free (3-subunits also had appeared in the culture medium.
As was found in some of the tumor patients, the concentrations of the free subunits apparently exceeded that of holo-hCG. Figure 5 presents two examples of a longitudinal retrospective study of two patients with trophoblastic tumors. These data emphasize the variety of different constellations of discordant hCG values that can be observed, which are attributable to an unbalanced secretion of holo-hCG and its subunits. This points to the possible risks that results will be falsely negative or clinical interpretations wrong when one relies solely on measurements of holo-hCG. Figure 6 shows a more detailed analysis of the secretion kinetics of "BeWo," a further choriocarcinoma cell line, which demonstrates that in these cells the free a-subunit is the earliest-appearing tumor marker and the free /3-subunit the latest. Similar to JAr, free (3-chains appeared in the medium, but not before the concentrations of holo-hCG had become constant.
Further experiments, summarized in Figure 7 , suggest that the unbalanced secretion by BeWo and JAr cells is a result of unbalanced intracellular biosynthesis.
Moreover, most free a-subunits seem to be associated with some insoluble, centrifugable, intracellular membranous fraction, whereas the free (3-subunits and holo-hCG both seem to be present only as solutes. In contrast to what we found for theculture medium, the concentrations of cytosolic a-and /3-subunits were approximately equal but, as was also true for the medium, higher than that of holo-hCG. These findings generally accord with those previously described by Hussa (27), who used chromatography and subunit-specific radioimmunoassays. Tables I and 2 ). Subunit concentrations were calculated by subtracting the holo-hCG content from the composite concentration readings in the respective subunit-erMAs. The a,mwe denote initiation of a two-to three-month polychemotherapy. Holo-hCG #{149}, a-subunit p-subunit 0. Note, that at certain times the concentration of holo-hCG and ofthe free subunits can be nearly equal (e.g., in patient B at time 0 or iSO days), or can be totally discordant (e.g. in patient A at time 0 or 90 days) or discordant with respect to only one of the two subunits that maybe presentin equal (e.g., inpatientBat6Oor l5Odaysoras inpatientAat 150 days) or in grossly increased concentrations (as free p-subunit In patient A or free a-subunit in patient B at the respective ends of the observation period). Note further that no free p-subunit was detectable in patient A during the 90 days of observation. However, holo-hCG was present, as shown, so this measurement of only p-subunit of hCG would represent a falsely negative result. In patient B, the values for holo-hCG and free p-subunitupon institution and maintenance of chemotherapy (from day 150 onwards) would indicate tumor regression, yet the dramatic increase of free a-subunit levels after day 180 would favor a totally differentclinical interpretation Ag. 6.lime-course experiment concerning thesecretofy capability of BeWo choriocarcinoma cells inculture
The cells were kept under the recommended conditions in our hythdoma culture unit. They were washed as soon as about three-fourths of the available growth area of the culture flasks were covered. Subsequently, the medium was exchanged for a fresh 75-mL lot, from which at the time intervals shown we withdrew the indicated 1-mL aliquots, froze them and later simultaneously thawed and assayed them In parallel by the three epitope-selective IRMAS (as shown in Tables 1 and 2 Tables 1 and 2 ). It is evident that the concentrations of the subunits in both samples were higher than that of holo-hCG, reflecting an unbalanced content of these hCG-species In the cytoplasm. However, the content of freea-subunits decreased to about 70% in the centrifuged samples (= cytosol) while the concentrations of holo-hCG and free p-subunits remained unchanged as compared with those determined in the raw homogenate
Discussion
Before the accuracy of immunoas8ays can be enhanced one must know the inununochemistry of a given analyte. Here we have described some novel principles for establish-ing ms by exploiting the repertoire of many different specificitiescontained in a set of MCA that were raised by immunization with only one antigen, hCG. By characterizing their epitope specificities, we have also assessed the number of epitopes of hCG as well as their topographical localizations on this molecule (1). In particular, we found that each subunit possesses at least two distinct epitopes and that these are sufficiently distant from each other to permit the simultaneous or sequential attachment of two MCA to each of them, which in fact is the prerequisite for a two-site ("sandwich") nu.
We preferred this technique, which per se requires higher antibody concentrations, over one-site competitive radioimmunoassay because it compensates for the oft-observed lower affinity of MCA as compared with polyclonal antisera.
There are special analytical problems pertaining to hCG measurements because this substance, like many others, occurs not as a single molecular entity but rather in multiple forms such as holo-hCG, free a-, or free 13-subunits (2, 10, 13-16, 20) . It remains to be clarified whether these have to be considered as split products of metabolized holehCG (such as free /3-subunits in pregnancy urines) or as somehow-altered precursor subunits that cannot be assembled as intact hCG before secretion (such as in some tumor cells).
Unfortunately, we have initially screened our anti-hCG hybridomas only with I-labeled holo-hCG. Perhaps we have therefore discarded those clones that were directed against "private" epitopes of the subunits that are hidden on the intact a:/3-dimer molecule. This is the reason for a major disadvantage of the present analytical design: free subunits are measured together with holo-hCG, thus are determined only indirectly, by subtracting the results for the holo-hCGmr from those for the subunit-mrs.
Hence, free subunits can reliably detected only if their concentrations amount to a certain proportion of that of holo-hCG-i.e., about 20%-that roughly corresponds to double the imprecision of the method. Still, however, when hCG is below detectability, even minute amounts of free subunits can be measured, such as has been demonstrated in the time-course experiments of the choi-iocarcinoma cell lines (Table 2 , Figures 6,   7) .Use of MCA against private subunit-epitopes would allow for the rearrangement of the concept presented here in such a way that one could also quantifr isolated subunits independently, even in the presence of high concentrations of holo-hCG. Such ms for free /3-subunits have recently been reported (28,29), but none as yet for free a-subunits.
Nevertheless, the usefulness of the present zaMAs has been tested in several analytical applications:
Firstly, we could assess the purity, composition, and behavior of different standard preparations for hCG and related glycoprotein hormones; many of those "discordant hCG.-results" (59) presumably can be explained on this basis and attributed to either cross reactivity of the binding reagents or ill-defined content of standard or sample (or both) with respect to free subunits. Secondly, assay of urine and serum from normal and pregnant subjects as well as from various carcinoma patients revealed quite marked differences between these groups and also within a given group. From the findings thus far obtained, one may infer that the current reliance on radioimmunoassays for /3-hCG alone are likely to be of insufficient diagnostic sensitivity and specificity for the detection as well as management of hCG-producing tumors.
For example, as the time-course data of JAr, of BeWo, and of patients A and B (in Figure 5) suggest, measurement of the free /3-subunits alone would indicate at certain times the absence of tumor or that there was regression (successful therapy) when this is in fact not necessarily so, as would be recognized if free a-subunits or holo-hCG (or both) were also evaluated.
Although these data are preliminary, we conclude that in this particular clinical-diagnostic context free a-and /3-subunits and holo-hCG should be simultaneously measured in each sample, as also advocated previously by others (9, 10, 14). What we wanted to do in this study was to demonstrate that immunoassays, especially nuas, that comply with such diagnostic requirements can indeed be installed without difficulty. Based on an epitope map of the analyte in question and on the availability of MCA with defined epitope specificities, such IRMAS can be theoretically planned, and their discrete analytical specificities can be exactly predicted and finally verified. Thus it should be possible to approach on a larger prospective scale the issue as to which of these analytes is of greatest diagnostic relevance in which type of specimen. Our data support those of others (2, 10, 13, 14) that the free a-subunit deserves greater a,ttention than hitherto generally recognized. 
